Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancerStudy ...
In this video, Rebecca Stone, MD, MS, discussed the need for improved prevention and screening methods for ovarian cancer.
A new study published in the Journal of the American Medical Association revealed that the chance of developing serous ...
The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr.
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ...
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) March 4 (Reuters) - Adding a minimally invasive laser procedure to ...
High-grade astrocytoma, which includes glioblastoma, is a fast-growing, aggressive brain cancer that often returns after the ...
Currently, no consensus exists regarding the definition of oligometastatic pancreatic ductal adenocarcinoma, its necessary diagnostic measures, and potential treatment approaches. To address these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results